Make my Trip to the Bank - MMYT
Make My Trip to the Bank
MMYT up 88%
We Alerted our Members ahead of time, we went through reams of Data and researched all the sources that are available to make sure that we get this right. Despite the Broad Market getting beaten up for last few days.
We thought the Two IPO's we profiled are great for long term investors, who could afford to invest their risk capital for huge gains.
We are glad that our members were able to profit handsomely...........
The mighty, Make my Trip was a real treat, it was a TRIP to the BANK, a whopping 88% Gainer for our Members!!!!
After hours update: 08/12/10
Bulls look at IPO's for Relief! Summer Rally Fizzled
As Summer rally fizzles
Bulls look at IPO's for Relief!
This summer has been the hottest on record, scorching heat waves left nothing for bulls to graze on. Gored by the bad employment numbers, declining consumer confidence their hopes further dashed by the grim economic out look by the Fed, which sent stocks into a tailspin.
This year IPO market has not been great either, with a few exceptions, majority of IPO's are getting priced at the lower end. Keeping that in mind, we focus on Two IPO's that are coming to the Market this week, these Two could reward handsomely for long term investors with huge appetite for risk.
-
MakeMyTrip - MMYT- is an India based online travel site with over 40% share of the domestic travel market, rising middle class and increasing online shopping trend will help this company retain its leading position in the near future. There are other lesser known domestic travel sites as well as the well known international sites like Expedia and Priceline that are aggressively competing for the market share. Our hunch is one of the International sites may decide to partner with or buy a stake in the company rather than build from the ground up.
-
Kanghui Holdings – KH – is a China based maker of orthopedic implants. There is a huge potential market for the aging and increasingly affluent Chinese population. Hip replacement and Knee replacement use to be a rare and true luxury for the ultra-rich few Chinese, who could afford to travel abroad or nearby Hong Kong or Singapore for such procedures. This company could be a huge beneficiary of the fast growing private health service sector.
source: The Company(s), OxBridgeResearch, PennyStockMonster, OTCking
category: IPO, Fed, Travel, Health, Chinese Stocks, Indian Stocks.
A20100812
Yucheng Technologies| YTEC | Profile | Summary
Yucheng Technologies| YTEC | Profile | Summary
China’s growing banking and service sector is robust as ever. China’s GDP still Growing at 8% a year. AgBank of China recently raised $20 Billion Dollars in a massive Global Initial Public Offering of its kind.
Yucheng Technologies Limited (Yucheng) is a provider of information technology (IT), software, solutions and services to China's banking sector. Based on the nature of its solutions and services, Yucheng categorizes them as Software & Solutions, and Platform & Maintenance Services (POS). Software & Solutions includes the development and sale of the Company's software solutions, IT consulting and implementation, and customized software development. Platform & Maintenance Services relates to the procurement, re-sale, installation, integration and maintenance of third-party hardware and software.
Source: The Company, OxBridgeResearch, PennyStockMonster
Category: Banking, POS, Saas, IT, Online Payment system
A20100806
TSRX | Trius Therapeutics | Profile | Summary
TSRX | Trius Therapeutics | Profile | Summary
Trius Therapeutics, TSRX, has just raised $50 Million Dollars. The interesting thing about the company's IPO was, the size and the price of the offering was cut down almost in half before the IPO, thus providing an excellent opportunity and a little cushion for those who buy the stock in the open market.
We believe this could be a good opportunity for investors with long term horizon and risk tolerance. Remember after all it is developing a drug that has not been approved by the FDA yet. We also like to point out that it is suitable only for investors with high degree of risk tolerance and who are not looking for a quick pop.
TSRX is developing life-threatening bacterial infections like the antibiotic-resistant strains of staph infections, known as MRSA. The company says its drug is more potent and can be easily administered than what is currently being offered . In addition it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by bacteria of the gram-negative and gram-positive categories.
Source: The Company, OxBridgeResearch, PennyStockMonster, OTCking
Category: MRSA, Staph infection, IPO, Bio Pharma, Bio Thech.
A20100805
Feed Entries
